ClinicalTrials.gg
RecruitingNCT05743426Updated Nov 20, 2026

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

An observational study in Sarcoma and Gastrointestinal Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Nov 20, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Planned enrollment
29th of 100
450 · median 101
Started
2023
with 33 others
Observational
100 of 958
30 open now
Primary completion
2036-01
later than 236 of 240 live
Registered
831st of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 29th largest by planned enrollment of the 100 observational ones that give a count, is one of 34 that started in 2023, is one of 100 observational ones, reaches primary completion later than 236 of the 240 other live ones, and was the 831st registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.

Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.

03

Conditions studied

  • Sarcoma
  • Gastrointestinal Cancer

Keywords

  • toxicity
  • survey
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with gastrointestinal malignancy or sarcoma receiving treatment at study center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to participate in this study a subject must meet all of the eligibility criteria outlined below.

  1. Subject is willing and able to provide written to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer.
  2. Age ≥ 18 years at the time of consent.
  3. Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal or sarcoma.
  4. Females with and male subjects with fathering potential are allowed to participate in this study.

Exclusion criteria

Exclusion Criteria

All subjects meeting any exclusion criteria at baseline will be excluded from study participation.

  1. Inability or unwillingness to provide
  2. Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single Arm

    Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.

    Other: Survey · Other: Toxicity Assessments

Interventions

  • OtherSurvey

    Patient Reported Outcome (PRO) questionnaire

  • OtherToxicity Assessments

    Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    Disease-free survival is defined as the length of time after treatment in which the subject survives with no signs or symptoms of cancer.

    Time frame: Up to 10 years

Secondary outcomes

  1. Local Control

    Local Control is defined as radiographic and clinical assessments determined by the patient's treating physician.

    Time frame: Up to 10 years

  2. Adverse Events

    The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5 is a descriptive terminology that can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

    Time frame: Up to 10 years

  3. Quality of life PRO-CTCAE

    Quality of life PRO-CTCAE will be evaluated using patient-reported quality of life The PRO-CTCAE is a measurement system that characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities that include pain, fatigue, nausea, and cutaneous side effects such as rash and hand-foot syndrome, all toxicities that can be meaningfully reported from the patient's perspective. PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present).

    Time frame: Up to 10 years

  4. Quality of life EQ-5D-5L

    Quality of life EQ-5D-5L will be evaluated using EQ-5D-5L. The EQ-5D-5L is a QoL assessment that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5) to extreme problems.

    Time frame: Up to 10 years

  5. Quality of life Toronto Extremity Salvage Score (TESS)

    Toronto Extremity Salvage Score (TESS) quality of life questionnaire will be used in subjects with sarcoma. The TESS is a 30-item patient-reported outcome questionnaire that addresses daily activity limitations including restrictions in body movement, mobility, self-care, and performance of daily tasks. It is scored from 0 (not possible) to 5 (without any problem). Higher scores indicate less functional limitation.

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
  • University of North Carolina at Chapel Hill, Department of Radiation Oncology
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Victoria Xu · Contactvictoria_xu@med.unc.edu · 984-974-8744
    • Theodore K Yanagihara, MD · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jan 2036, 153 months after the start.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 153 months is above that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 24, 2023
StartActual
Mar 17, 2023
Primary completionEst.
Jan 1, 2036
CompletionEst.
Jan 1, 2036
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
180→450
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Enrollment 180→450
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05743426
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Mar 17, 2023
Primary completion
Jan 1, 2036 (estimated)
Completion
Jan 1, 2036 (estimated)
Last update
Nov 20, 2026

Study contacts

Victoria Xu, MD, PhD
Contact
victoria_xu@med.unc.edu
+1 984-974-8744
Olivia Roberts
Contact
olivia_roberts@med.unc.edu
Theodore K Yanagihara
principal investigator · Lineberger Comprehensive Cancer Center, The University of North Carolina Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion